Background: In modern obstetrics, labour induction is considered a way to improve maternal and foetal outcomes. In this regard, an increase in the frequency of induced labour has been noted worldwide. However, some evidence suggests that elective labour induction prolongs hospital stay and may increase costs and resource utilisation. Considering these provisions, and also the fact that some women prefer to be at home as long as possible before delivery, outpatient cervical ripening could be a reasonable alternative. Material and methods: This study was open-label randomized controlled trial conducted in the Department of Obstetrics and Gynaecology, King George’s Medical University, Lucknow, over a time period of 1 year from August 2018 to August 2019 enrolled women who were admitted to the labor room at term with indications of induction of labor, willing to participate in the trial. Result: The age of the patients ranged from 18 to 33 years. The mean age in the Mifepristone group was 25.10±3.50 years, and in the Dinoprostone group, it was 24.80±3.40 years (p=0.685). In the Mifepristone group, 30 (55%) were primigravida, and 25 (45%) were multigravida, while in the Dinoprostone group, 31 (57%) were primigravida, and 23 (43%) were multigravida (p=0.710). Conclusion: Misoprostol an analogue of PGE1 appear to be perfect substitute for induction of labour. Its use was found to be associated with reduced time to delivery and high rate of vaginal delivery within 12 and 24 hours of induction. The requirement for oxytocin in augmentation was substantially reduced.